In this post we ask what about the patient when healthcare providers plan treatment changes to save money. Is too much emphasis placed on the cost of care?
Tag: nhs england
Some people have asked me for links to or further reading on the original decision and announcement by the NHS to move to biosimilars at the end of biologics patents in 2018. Below are a couple of high level ones that came out at the time of the announcement. Note […]